Search results
Results from the WOW.Com Content Network
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
On 16 April 2021, the FDA revoked the emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. [69]
Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.
The timeline of the COVID-19 pandemic lists the articles containing the chronology and epidemiology of SARS-CoV-2, [1] the virus that causes the coronavirus disease 2019 and is responsible for the COVID-19 pandemic. The first human cases of COVID-19 occurred in Wuhan, People's Republic of China, on or about 17 November 2019. [2]
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies .
By late November 2019, coronavirus disease 2019 had broken out in Wuhan, China. [2]As reported in Clinical Infectious Diseases on November 30, 2020, 7,389 blood samples collected between December 13, 2019, and January 17, 2020, by the American Red Cross from normal donors in nine states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington and Wisconsin ...
The species was merged with Rat coronavirus (discovered in 1970 [23]) and Puffinosis coronavirus (discovered in 1982 [59]) as Murine coronavirus in 2009. [ 60 ] 229E and OC43 were collectively named Human respiratory virus but merged as Human coronavirus 229E (HCoV-229E) in 2009 . [ 61 ]
The development of the Pfizer- BioNTech COVID‑19 vaccine began when BioNTech founder and CEO Uğur Şahin while at his home in Mainz on Friday 24 January 2020, was checking out his regular websites when he noted a report in the science section of Der Spiegel website about novel respiratory illness that had affected approximately 50 people in ...